19 June 2019 - NICE has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia. 

The indication is for patients in first complete remission with minimal residual disease activity of at least 0.1%.

This decision to recommend the drug as a cost-effective use of NHS resources follows the submission of new evidence from the company during consultation on earlier draft recommendations.

Amgen has a confidential commercial arrangement which will make the drug available to the NHS with a discount.

Read Pharma Times article